Listed

Vivani Medical, Inc.

VANINasdaqCIK 1266806HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2025
Operating income−$6.9m, Q2 FY2026
Net income−$6.4m, Q2 FY2026
Vivani Medical, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$knot reportednot reportednot reportednot reported0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2024-11-13, accession 0001753926-24-001874. Derived: 9-month figure less the 6-month figure.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-31, accession 0001753926-25-000527. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-05-13, accession 0001753926-25-000794.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-13, accession 0001753926-25-001330. Derived: 6-month figure less the 3-month figure.Report this figurenot reportednot reportednot reportednot reported
Cost of revenue$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Gross profit$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$k4,441Research and development, Q3 FY2023, three months to 2023-09-30$4.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0001753926-24-001874.Report this figure4,708Research and development, Q4 FY2023, three months to 2023-12-31$4.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-31, accession 0001753926-25-000527. Derived: 12-month figure less the 9-month figure.Report this figure3,726Research and development, Q1 FY2024, three months to 2024-03-31$3.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001753926-25-000794.Report this figure3,513Research and development, Q2 FY2024, three months to 2024-06-30$3.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-13, accession 0001753926-25-001330.Report this figure4,203Research and development, Q3 FY2024, three months to 2024-09-30$4.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure4,303Research and development, Q4 FY2024, three months to 2024-12-31$4.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001753926-26-000548. Derived: 12-month figure less the 9-month figure.Report this figure4,217Research and development, Q1 FY2025, three months to 2025-03-31$4.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure4,759Research and development, Q2 FY2025, three months to 2025-06-30$4.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure4,519Research and development, Q3 FY2025, three months to 2025-09-30$4.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure4,630Research and development, Q4 FY2025, three months to 2025-12-31$4.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001753926-26-000548. Derived: 12-month figure less the 9-month figure.Report this figure4,390Research and development, Q1 FY2026, three months to 2026-03-31$4.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure4,456Research and development, Q2 FY2026, three months to 2026-06-30$4.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure
Operating income$k(7,144)Operating income, Q3 FY2023, three months to 2023-09-30−$7.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001753926-24-001874.Report this figure(6,217)Operating income, Q4 FY2023, three months to 2023-12-31−$6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001753926-25-000527. Derived: 12-month figure less the 9-month figure.Report this figure(6,227)Operating income, Q1 FY2024, three months to 2024-03-31−$6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001753926-25-000794.Report this figure(5,681)Operating income, Q2 FY2024, three months to 2024-06-30−$5.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-13, accession 0001753926-25-001330.Report this figure(6,309)Operating income, Q3 FY2024, three months to 2024-09-30−$6.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure(6,460)Operating income, Q4 FY2024, three months to 2024-12-31−$6.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001753926-26-000548. Derived: 12-month figure less the 9-month figure.Report this figure(6,557)Operating income, Q1 FY2025, three months to 2025-03-31−$6.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure(7,462)Operating income, Q2 FY2025, three months to 2025-06-30−$7.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure(6,725)Operating income, Q3 FY2025, three months to 2025-09-30−$6.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure(6,810)Operating income, Q4 FY2025, three months to 2025-12-31−$6.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001753926-26-000548. Derived: 12-month figure less the 9-month figure.Report this figure(6,817)Operating income, Q1 FY2026, three months to 2026-03-31−$6.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure(6,874)Operating income, Q2 FY2026, three months to 2026-06-30−$6.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure
Net income$k(6,782)Net income, Q3 FY2023, three months to 2023-09-30−$6.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001753926-24-001874.Report this figure(6,026)Net income, Q4 FY2023, three months to 2023-12-31−$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001753926-25-000527. Derived: 12-month figure less the 9-month figure.Report this figure(6,039)Net income, Q1 FY2024, three months to 2024-03-31−$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure(5,356)Net income, Q2 FY2024, three months to 2024-06-30−$5.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure(6,041)Net income, Q3 FY2024, three months to 2024-09-30−$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure(6,050)Net income, Q4 FY2024, three months to 2024-12-31−$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001753926-26-000548. Derived: 12-month figure less the 9-month figure.Report this figure(6,302)Net income, Q1 FY2025, three months to 2025-03-31−$6.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure(7,144)Net income, Q2 FY2025, three months to 2025-06-30−$7.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure(6,530)Net income, Q3 FY2025, three months to 2025-09-30−$6.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure(6,633)Net income, Q4 FY2025, three months to 2025-12-31−$6.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001753926-26-000548. Derived: 12-month figure less the 9-month figure.Report this figure(6,780)Net income, Q1 FY2026, three months to 2026-03-31−$6.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure(6,370)Net income, Q2 FY2026, three months to 2026-06-30−$6.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure
Diluted EPS$ per share(0.13)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001753926-24-001874.Report this figurenot reported(0.12)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001753926-25-000794.Report this figure(0.10)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-13, accession 0001753926-25-001330.Report this figure(0.11)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figurenot reported(0.11)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure(0.12)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure(0.11)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figurenot reported(0.08)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure(0.07)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure
Basic EPS$ per share(0.13)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001753926-24-001874.Report this figurenot reported(0.12)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.12 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0001753926-25-000794.Report this figure(0.10)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-13, accession 0001753926-25-001330.Report this figure(0.11)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figurenot reported(0.11)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure(0.12)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure(0.11)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figurenot reported(0.08)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure(0.07)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure

Balance sheet

Cash and equivalents$19.9m, Q2 FY2026
Shareholders' equity$19.0m, Q2 FY2026
Vivani Medical, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m24.8Cash and equivalents, Q3 FY2023, at 2023-09-30$24.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-13, accession 0001753926-23-001474.Report this figure20.7Cash and equivalents, FY2023, at 2023-12-31$20.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-31, accession 0001753926-25-000527.Report this figure29.6Cash and equivalents, Q1 FY2024, at 2024-03-31$29.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-13, accession 0001753926-24-000959.Report this figure24.9Cash and equivalents, Q2 FY2024, at 2024-06-30$24.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-13, accession 0001753926-24-001420.Report this figure19.6Cash and equivalents, Q3 FY2024, at 2024-09-30$19.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0001753926-24-001874.Report this figure18.4Cash and equivalents, FY2024, at 2024-12-31$18.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-26, accession 0001753926-26-000548.Report this figure13.0Cash and equivalents, Q1 FY2025, at 2025-03-31$13.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0001753926-25-000794.Report this figure6.8Cash and equivalents, Q2 FY2025, at 2025-06-30$6.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-13, accession 0001753926-25-001330.Report this figure2.6Cash and equivalents, Q3 FY2025, at 2025-09-30$2.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure16.2Cash and equivalents, FY2025, at 2025-12-31$16.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure19.7Cash and equivalents, Q1 FY2026, at 2026-03-31$19.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure19.9Cash and equivalents, Q2 FY2026, at 2026-06-30$19.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure
Current assets$m30.7Current assets, Q3 FY2023, at 2023-09-30$30.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-13, accession 0001753926-23-001474.Report this figure23.1Current assets, FY2023, at 2023-12-31$23.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0001753926-25-000527.Report this figure31.5Current assets, Q1 FY2024, at 2024-03-31$31.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-13, accession 0001753926-24-000959.Report this figure26.3Current assets, Q2 FY2024, at 2024-06-30$26.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0001753926-24-001420.Report this figure21.4Current assets, Q3 FY2024, at 2024-09-30$21.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001753926-24-001874.Report this figure20.4Current assets, FY2024, at 2024-12-31$20.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-26, accession 0001753926-26-000548.Report this figure14.9Current assets, Q1 FY2025, at 2025-03-31$14.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0001753926-25-000794.Report this figure8.7Current assets, Q2 FY2025, at 2025-06-30$8.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-13, accession 0001753926-25-001330.Report this figure4.2Current assets, Q3 FY2025, at 2025-09-30$4.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure17.9Current assets, FY2025, at 2025-12-31$17.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure21.5Current assets, Q1 FY2026, at 2026-03-31$21.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure21.6Current assets, Q2 FY2026, at 2026-06-30$21.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure
Total assets$m53.3Total assets, Q3 FY2023, at 2023-09-30$53.3m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-13, accession 0001753926-23-001474.Report this figure45.8Total assets, FY2023, at 2023-12-31$45.8m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0001753926-25-000527.Report this figure53.8Total assets, Q1 FY2024, at 2024-03-31$53.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-13, accession 0001753926-24-000959.Report this figure48.2Total assets, Q2 FY2024, at 2024-06-30$48.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0001753926-24-001420.Report this figure42.9Total assets, Q3 FY2024, at 2024-09-30$42.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001753926-24-001874.Report this figure41.6Total assets, FY2024, at 2024-12-31$41.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-26, accession 0001753926-26-000548.Report this figure35.5Total assets, Q1 FY2025, at 2025-03-31$35.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0001753926-25-000794.Report this figure28.9Total assets, Q2 FY2025, at 2025-06-30$28.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-13, accession 0001753926-25-001330.Report this figure25.0Total assets, Q3 FY2025, at 2025-09-30$25.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure39.4Total assets, FY2025, at 2025-12-31$39.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure42.4Total assets, Q1 FY2026, at 2026-03-31$42.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure41.6Total assets, Q2 FY2026, at 2026-06-30$41.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure
Current liabilities$m7.4Current liabilities, Q3 FY2023, at 2023-09-30$7.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-13, accession 0001753926-23-001474.Report this figure5.7Current liabilities, FY2023, at 2023-12-31$5.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0001753926-25-000527.Report this figure6.1Current liabilities, Q1 FY2024, at 2024-03-31$6.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-13, accession 0001753926-24-000959.Report this figure5.8Current liabilities, Q2 FY2024, at 2024-06-30$5.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0001753926-24-001420.Report this figure6.3Current liabilities, Q3 FY2024, at 2024-09-30$6.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001753926-24-001874.Report this figure6.0Current liabilities, FY2024, at 2024-12-31$6.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-26, accession 0001753926-26-000548.Report this figure6.2Current liabilities, Q1 FY2025, at 2025-03-31$6.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0001753926-25-000794.Report this figure6.7Current liabilities, Q2 FY2025, at 2025-06-30$6.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-13, accession 0001753926-25-001330.Report this figure6.8Current liabilities, Q3 FY2025, at 2025-09-30$6.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure6.6Current liabilities, FY2025, at 2025-12-31$6.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure6.8Current liabilities, Q1 FY2026, at 2026-03-31$6.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure6.7Current liabilities, Q2 FY2026, at 2026-06-30$6.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure
Total liabilities$m27.1Total liabilities, Q3 FY2023, at 2023-09-30$27.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-13, accession 0001753926-23-001474.Report this figure25.0Total liabilities, FY2023, at 2023-12-31$25.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0001753926-25-000527.Report this figure25.1Total liabilities, Q1 FY2024, at 2024-03-31$25.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-13, accession 0001753926-24-000959.Report this figure24.4Total liabilities, Q2 FY2024, at 2024-06-30$24.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0001753926-24-001420.Report this figure24.6Total liabilities, Q3 FY2024, at 2024-09-30$24.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001753926-24-001874.Report this figure24.0Total liabilities, FY2024, at 2024-12-31$24.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-26, accession 0001753926-26-000548.Report this figure23.8Total liabilities, Q1 FY2025, at 2025-03-31$23.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0001753926-25-000794.Report this figure24.0Total liabilities, Q2 FY2025, at 2025-06-30$24.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-13, accession 0001753926-25-001330.Report this figure23.7Total liabilities, Q3 FY2025, at 2025-09-30$23.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure23.7Total liabilities, FY2025, at 2025-12-31$23.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure23.3Total liabilities, Q1 FY2026, at 2026-03-31$23.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure22.7Total liabilities, Q2 FY2026, at 2026-06-30$22.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m26.2Shareholders' equity, Q3 FY2023, at 2023-09-30$26.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001753926-24-001874.Report this figure20.8Shareholders' equity, FY2023, at 2023-12-31$20.8m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-26, accession 0001753926-26-000548.Report this figure28.7Shareholders' equity, Q1 FY2024, at 2024-03-31$28.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure23.8Shareholders' equity, Q2 FY2024, at 2024-06-30$23.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure18.3Shareholders' equity, Q3 FY2024, at 2024-09-30$18.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure17.6Shareholders' equity, FY2024, at 2024-12-31$17.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure11.6Shareholders' equity, Q1 FY2025, at 2025-03-31$11.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure4.9Shareholders' equity, Q2 FY2025, at 2025-06-30$4.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure1.3Shareholders' equity, Q3 FY2025, at 2025-09-30$1.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure15.7Shareholders' equity, FY2025, at 2025-12-31$15.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure19.1Shareholders' equity, Q1 FY2026, at 2026-03-31$19.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure19.0Shareholders' equity, Q2 FY2026, at 2026-06-30$19.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure

Cash flow

Operating cash flow−$6.0m, Q2 FY2026
Capital expenditure$99.0k, Q2 FY2026
Vivani Medical, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(7,702)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$7.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001753926-24-001874. Derived: 9-month figure less the 6-month figure.Report this figure(3,481)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001753926-25-000527. Derived: 12-month figure less the 9-month figure.Report this figure(4,512)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$4.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001753926-25-000794.Report this figure(4,801)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$4.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-13, accession 0001753926-25-001330. Derived: 6-month figure less the 3-month figure.Report this figure(5,661)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$5.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001753926-25-001770. Derived: 9-month figure less the 6-month figure.Report this figure(5,812)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$5.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001753926-26-000548. Derived: 12-month figure less the 9-month figure.Report this figure(5,163)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure(6,087)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$6.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001753926-26-001477. Derived: 6-month figure less the 3-month figure.Report this figure(6,351)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$6.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001753926-25-001770. Derived: 9-month figure less the 6-month figure.Report this figure(6,719)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$6.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001753926-26-000548. Derived: 12-month figure less the 9-month figure.Report this figure(6,196)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$6.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure(6,035)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$6.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001753926-26-001477. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k63.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$63.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0001753926-24-001874. Derived: 9-month figure less the 6-month figure.Report this figure743Capital expenditure, Q4 FY2023, three months to 2023-12-31$743.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-31, accession 0001753926-25-000527. Derived: 12-month figure less the 9-month figure.Report this figure182Capital expenditure, Q1 FY2024, three months to 2024-03-31$182.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-13, accession 0001753926-25-000794.Report this figure37.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$37.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-13, accession 0001753926-25-001330. Derived: 6-month figure less the 3-month figure.Report this figure41.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$41.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001753926-25-001770. Derived: 9-month figure less the 6-month figure.Report this figure296Capital expenditure, Q4 FY2024, three months to 2024-12-31$296.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001753926-26-000548. Derived: 12-month figure less the 9-month figure.Report this figure5.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$5.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure71.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$71.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001753926-26-001477. Derived: 6-month figure less the 3-month figure.Report this figure823Capital expenditure, Q3 FY2025, three months to 2025-09-30$823.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001753926-25-001770. Derived: 9-month figure less the 6-month figure.Report this figure274Capital expenditure, Q4 FY2025, three months to 2025-12-31$274.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001753926-26-000548. Derived: 12-month figure less the 9-month figure.Report this figure3.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$3.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure99.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$99.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001753926-26-001477. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)87.09m, Q2 FY2026
Vivani Medical, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.0Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3038,477 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-13, accession 0001753926-23-001474.Report this figure0.1Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3150,755 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-05-15, accession 0001753926-23-000655.Report this figure50.8Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3050,795,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0001753926-24-001420.Report this figure50.8Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3050,837,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001753926-24-001874.Report this figure52.2Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3152,202,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0001753926-25-000794.Report this figure55.0Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3055,021,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-13, accession 0001753926-25-001330.Report this figure55.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3055,247,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure59.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3159,236,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure59.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3059,244,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure59.7Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3059,711,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001753926-25-001770.Report this figure81.3Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3181,269,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001753926-26-000852.Report this figure87.1Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3087,090,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure

Shares outstanding: 90.20mShares outstanding, period not labelled, at 2026-08-1390,203,356 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001753926-26-001477.Report this figure at Aug 13, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. Listed shows no prices and gives no investment advice.